The South African Health Products Regulatory Authority (SAHPRA) issued an urgent recall of compounded GLP-1 medicines due to regulatory non-compliance.
This action targets medications used for diabetes and weight loss, including compounded versions of Ozempic, Wegovy, and Mounjaro [1]. Because these drugs affect metabolic functions and glucose levels, non-compliant versions pose significant risks to patient safety and public health.
The recall focuses on products manufactured by iDexis, which operates as Sentra Pharmacy in Pretoria [2]. SAHPRA determined that these compounded medicines failed to meet the agency's quality and safety regulations [3].
Vincent Tlala, Registrar of the South African Pharmacy Council, said the recall is being undertaken to protect public health after the council identified non-compliance in the compounded GLP-1 products [4]. The regulatory body is working to ensure that medications distributed to the public meet strict national standards.
Patients who have used these specific compounded versions are urged to stop use immediately. A SAHPRA spokesperson said patients are urged to return the products to their healthcare provider or pharmacy for reimbursement [5].
Compounded drugs are typically custom-mixed by pharmacists to meet a specific patient's needs, but they do not undergo the same rigorous approval process as brand-name pharmaceuticals. The current crisis in South Africa highlights the risks associated with the proliferation of these unofficial alternatives to high-demand weight-loss medications [2].
“The recall is being undertaken to protect public health”
The recall underscores the growing regulatory struggle to manage the surge in demand for GLP-1 agonists. When official supplies of medications like Ozempic and Mounjaro are limited or expensive, patients often turn to compounded alternatives. However, these versions lack standardized oversight, and this enforcement action by SAHPRA signals a crackdown on pharmacies that bypass safety protocols to capitalize on the weight-loss drug trend.
